Kolexia
Game Laurence Pneumologie
Game Laurence
Pneumologie
Hôpital Larrey Toulouse
Toulouse, France
142 Activités
29 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Thymome Tumeurs du thymus Métastase tumorale Adénocarcinome Tumeurs du cerveau

Collaborateurs

Voir plus
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Greillier Laurent
Greillier Laurent
Hôpital Nord Marseille, Marseille, France
Guisier Florian
Guisier Florian
Hôpital Charles Nicolle, Rouen, France
Decroisette Chantal
Decroisette Chantal
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
A+A
112 collaboration(s)
Dernière en 2023
IQVIA
78 collaboration(s)
Dernière en 2023
B3TSI
68 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
32 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Essai Clinique (National Cancer Institute)   21 mars 2024
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma: An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Essai Clinique (Roche)   20 mars 2024
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer: A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Essai Clinique (Dwight Owen)   12 mars 2024
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Essai Clinique (Jiangsu Alphamab Biopharmaceuticals Co., Ltd)   10 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
ROSIE: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma: A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Essai Clinique (National Cancer Institute)   03 février 2024
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Targeted oncology   15 novembre 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Journal of immunotherapy (Hagerstown, Md. : 1997)   09 octobre 2023
Le cancer bronchique du sujet jeune: Lung cancer in young patients
Revue des maladies respiratoires actualites   01 octobre 2023